You are here: Industry Insights > CORVax12

News List

OncoSec Announces First Subjects Dosed in Phase 1 Trial of COVID-19 Vaccine americanpharmaceuticalreview
January 28, 2021
OncoSec Medical Incorporated has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19.
OncoSec Announces FDA Clearance for Trial of COVID-19 Vaccine Candidate americanpharmaceuticalreview
November 09, 2020
OncoSec Medical announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a first-in-human Phase 1 trial for CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2 that the Company ...
FDA approves first-in-human trial of COVID-19 vaccine candidate europeanpharmaceuticalreview
November 02, 2020
The safety and immunogenicity of CORVax12, a novel DNA-encodable COVID-19 vaccine, will be evaluated in 36 healthy volunteers.
OncoSec Collaborates with Providence Cancer Institute contractpharma
April 08, 2020
To conduct first-in-human trial of OncoSec's CORVax12, an investigational vaccine to prevent COVID-19.